Is HER2-positive uterine serous cancer aggressive?

Question

Hello doctor,

I am asking about my wife, who is 54 and was diagnosed with uterine serous carcinoma, a type of endometrial cancer, about five months ago. After her staging workup, her oncologist mentioned that her tumor tested positive for HER2 overexpression, and now they are talking about adding Trastuzumab to her chemotherapy. We are trying to understand why serous carcinoma needs HER2-targeted Herceptin when this is a uterine cancer, and we always thought Herceptin was only for breast cancer.

Her HER2 IHC came back 3+ positive on the pathology report. She already has a mildly reduced ejection fraction of 50% on her echocardiogram, which her cardiologist is concerned about, since Herceptin can affect the heart. Her current oncologist said clinical trials showed benefit, but my wife is scared of the cardiac side effects.

Is HER2 targeted therapy really standard now for this type of endometrial cancer, and how closely does the heart need to be monitored?
Also, does the HER2 positivity mean the cancer is more aggressive than the usual serous type?

Please help.

Thank you.

Answer 1

Hello,

Welcome to icliniq.com.

I am sorry to hear about your wife. I understand your concern, and your questions are very valid.

Although Trastuzumab (Herceptin) is most commonly known for treating HER2-positive breast cancer, it is not limited to breast cancer. Some uterine cancers, especially uterine serous carcinoma, can also overexpress HER2, and research over the last few years has shown that adding Trastuzumab to standard chemotherapy improves outcomes in these patients. Because your wife’s tumor is strongly HER2-positive (IHC 3+), this means the cancer is using the HER2 pathway to grow, and targeting it is now considered an evidence-based and increasingly standard approach for this subtype of endometrial cancer. HER2 positivity in uterine serous carcinoma is generally associated with a more aggressive biology compared to HER2-negative cases, which is why oncologists aim to treat it more precisely with targeted therapy. However, the benefit is that HER2 gives us a “target,” allowing more effective treatment rather than relying on chemotherapy alone.

Regarding the heart, your concern is very important. Trastuzumab can affect heart function and may worsen or cause cardiomyopathy, especially in patients who already have reduced ejection fraction. An EF (ejection fraction) of 50% is borderline low, so careful monitoring is essential, not a reason to automatically avoid treatment, but it does require caution. Typically, doctors perform an echocardiogram every three months during therapy, and if there is a drop in heart function, the drug may be paused or stopped. Often, cardiologists also start protective medications, like beta-blockers or ACE (angiotensin-converting enzyme) inhibitors, to reduce risk.

So, close monitoring is important. It is reasonable to discuss the risks versus benefits again with both teams, but many patients with mild heart dysfunction can still safely receive Trastuzumab under careful supervision.

Let me know if you have further questions.

Best wishes.

Regards.